Success Metrics

Active Trials
1(50%)

Phase Distribution

Ph not_applicable
1
50%
Ph phase_1
1
50%

Phase Distribution

1

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
N/ANon-phased studies
1(50.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

2

all time

Status Distribution
Active(1)
Terminated(1)

Detailed Status

Recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
1
Success Rate
N/A
Most Advanced
Phase 1

Trials by Phase

Phase 11 (50.0%)
N/A1 (50.0%)

Trials by Status

recruiting150%
withdrawn150%

Recent Activity

1 active trials
Showing 2 of 2
recruitingnot_applicable

Study Looking at Biomarkers in Ovarian Cancer

NCT03419689
withdrawnphase_1

Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy

NCT03607955

Clinical Trials (2)

Showing 2 of 2 trials
NCT03419689Not Applicable

Study Looking at Biomarkers in Ovarian Cancer

Recruiting
NCT03607955Phase 1

Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy

Withdrawn

All 2 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
2